[Study of the virulence of Actinobacillus pleuropneumoniae in finishing pigs as a basis for vaccination development].
For vaccine licensing data about efficiency and duration of protection are essential. Within the scope of the developement of a new subunit vaccine against Actinobacillus pleuropneumoniae (A.pp.) the protective efficiency over the whole length of the fattening period must be proven. This required infection experiments in finishing pigs. Eight pigs in the age of six months were infected experimentally into the trachea with an A.pp. serotyp 2 strain. To our knowledge data about the susceptibility of pigs of this age do not exist, so that the infectious dose for pigs of this age and this route of infection had to be determined. Two pigs each were infected with different doses of 10(10), 6 x 10(5), 8 x 10(3) and 2 x 10(3) CFU (colony forming units). The aim of the study was to produce a typical pleuropneumonia with fever and severe respiratory symptoms as well as characteristic pathomorphological lung alterations without loss of animals during the acute stage of infection. The pathogen should be cultivated from lung tissue. The recommended dose for testing the efficiency of vaccines turned out to be approximately 10(3) CFU A.pp. serotyp 2.
Hennig-Pauka
Isabel
I
Klinik für kleine Klauentiere und forensische Medizin und Ambulatorische Klinik, Stiftung Tierärztliche Hochschule Hannover. isabel.hennig@tiho-hannover.de
Baltes
Nina
N
Jacobsen
Ilse
I
Stratmann-Selke
Janin
J
Gerlach
Gerald-Friedrich
GF
Selbitz
Hans-Joachim
HJ
Waldmann
Karl-Heinz
KH
D000189:Actinobacillus Infections / Q000517:prevention & control / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae / Q000276:immunology* / Q000472:pathogenicity*; D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D015169:Colony Count, Microbial / Q000662:veterinary; D008168:Lung / Q000382:microbiology; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*; D037521:Virulence Factors / Q000276:immunology
D001428:Bacterial Vaccines; D037521:Virulence Factors